Ezecure

This invention introduces a novel anti-cancer therapy derived from structural modifications of ezetimibe, a known cholesterol absorption inhibitor. The modified compound has been designed to address ezetimibe’s limitations in bioavailability and metabolic stability, especially for oral administration in treating colorectal and other cancers. This new drug variant shows significantly improved pharmacokinetics and pharmacodynamics for dual inhibition of HDM2 and HDM4 (HDMX)—two important negative regulators of the tumour suppressor protein p53.